Annual Meeting, American Society of Hematology

Dozens of presentations advance multiple myeloma research at the 2024 American Society for Hematology (ASH) meeting
Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center,
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial
City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference
Researchers from City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ranked among the nation’s top 5 cancer centers by U.
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a
ReAlta Presenting New Results in aGVHD at American Society of Hematology 2024
By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting in San Diego, California for its drug candidate in acute Graft-versus-Host Disease (aGVHD),
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting,
Ossium Health to Participate at the 66th American Society of Hematology Annual Meeting and Exposition
Ossium Health will exhibit at the American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2024 in San Diego, CA.
BioPharma Dive2d
ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...
EurekAlert!3d
AML, sickle cell disease research among highlights of UC ASH abstracts
University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...
Fred Hutch7d
Fred Hutch PhD student honored by American Society of Hematology
Rasika Venkataraman, a third-year doctoral student working in the lab of Stanley C. Lee, PhD, at Fred Hutch Cancer Center, ...